Xanthomas Regression in an 8-Year-Old Boy Treated With Lomitapide
Related Experiment Video
Updated: Oct 26, 2025

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
Genovefa Kolovou1, Aleksandros Tsoutsinos2, Irene Mastorakou3
1Department of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece.
Abstract:
This case reports on an 8-year-old boy with homozygous familial hypercholesterolemia with large tuberous xanthomas over his hands, elbows, buttocks, knees, and feet. Lomitapide 40 mg daily (steadily increased) was added to his classical lipid-lowering therapy. A 50% reduction in the thickness, hardness, size, and color intensity of xanthomas was reported after 2 years of treatment. (Level of Difficulty: Intermediate.).
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Lipid Absorption
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...

